Novo Holdings Drops $104 Million Into Hemab Therapeutics, Signaling Strong Confidence at IPO Boom
Novo Holdings’ $104 M stake in Hemab Therapeutics signals strong confidence and could stabilize its IPO, boosting prospects for rare‑disease drug trials.
3 minutes to read